Muscular Dystrophy Treatment Market 2020 Global Demands with Size, Share Analysis and Industry Forecast to 2026
Muscular dystrophy is a group of genetic diseases, which is characterized by weakness of muscle tissues conditions. This is caused by genetic mutations, which interfere in the production of muscle protein dystrophin that is necessary to build muscles. Muscular dystrophy is a genetic disease, and its symptoms include shortening of muscles and tendons, curvature of spine, weakening of heart muscles leading to cardiac problems, and breathing problem. The most common forms of muscular dystrophies include Duchenne muscular dystrophy, Becker muscular dystrophy, myotonic disease, congenital disease, and Oculopharyngeal muscular dystrophy. The cure for any form of muscular dystrophy is currently unspecified, but the symptoms can be relived through physical therapy, exercise, rehabilitative devices like a powered wheelchair, respiratory care, and surgery.
Get Sample PDF Brochure with Impact of COVID19: https://www.coherentmarketinsights.com/insight/request-sample/914
The common muscular dystrophy types:
- Duchenne Muscular Dystrophy (DMD)
Most common form of muscular dystrophy in children are caused due to lack of protein dystrophin. Onset of symptoms is seen at the age of 3, generally wheelchair-bound by 12. Curvature in spine, heart, and lungs are the symptoms. Duchenne muscular dystrophy (DMD) is an X-linked disease predominantly affecting males, resulting in uniform muscle wasting. Death occurs due to respiratory failure in mid-twenties.
- Becker Muscular Dystrophy (BMD)
Similar to Duchenne, however, with later onset and slow progression of the illness. Death occurs in mid-forties.
- Oculopharyngeal Muscular Dystrophy (OMD)
Initially affect eyelids, throat, and face followed by pelvis and shoulder. The onset of illness is seen between the age 40 and 50.
- Myotonic Muscular Dystrophy (MSD)
Most common form of muscular dystrophy in adults also called as Steinert’s disease. This is characterized by the inability of muscles to relax after contraction. Cataracts, insomnia, and arrhythmia are the symptoms.
- Congenital Muscular Dystrophy (CMD)
The disease prevails from birth or before the age of 2. Significant impairment is caused by swift progression of the disease. Congenital muscular dystrophy (CMD) results in learning disabilities and mental retardation.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get an Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/914
Rising prevalence of muscular dystrophies with unspecific current medications are expected to fuel the muscular dystrophies treatment market
According to the Karger Journal in 2014, the global prevalence for muscular dystrophies accounted between 19.8 and 25.1 per 100,000 person every year with myotonic dystrophy (0.5-18.1 per 100,000), duchenne muscular dystrophy (1.7-4.2) and facioscapulohumeral muscular dystrophy (3.2-4.6 per 100,000) to be the most common types of disorders. The initial research phase of the therapies and ongoing clinical trials for the development of innovative products are expected to drive the global muscular dystrophy treatment market. Moreover, specific guidance for drug development for muscular dystrophy drugs published by the U.S. FDA in 2015, is expected to accelerate new drug development for the treatment of disorder. The emergence of disease-modifying therapies as a replacement for the unmet medical needs of patients, who are not amenable to mutation-specific drugs are expected to fuel growth of the global muscular dystrophy treatment market over the forecast period. However, fast prognosis of disorder and low treatment seeking rate due to delayed diagnosis are the major limiting factors, which are expected to hamper growth of the global muscular dystrophy treatment market.
The global muscular dystrophy treatment market is segmented on the basis of treatment, diagnosis, end user, and region.
On the basis of treatment, the global muscular dystrophy treatment market is segmented into:
- Angiotensin-Converting Enzyme (ACE) Inhibitors
- Physical Therapy
- Mobility Aids
- Breathing Assistance
- Molecular Therapy
- Gene Replacement Therapy
- Stem Cell Research
- Protein Production Alteration
- Myoblast Transplantation
On the basis of diagnosis, the global muscular dystrophy treatment market is segmented into:
- Enzyme Assay
- Genetic Testing
On the basis of end user, the global muscular dystrophy treatment market is segmented into:
- Home Care Settings
Got any Query? Feel free to ask us at : https://www.coherentmarketinsights.com/insight/talk-to-analyst/914
North America is expected to dominate the global market
Regional segmentation of the global muscular dystrophy treatment market by Coherent Market Insights comprises North America, Latin America, Europe, Asia Pacific, Middle East and Africa. According to the Centers for Disease Control and Prevention estimates in 2007, 349 out of 2.37 million males aged 5 to 24 years were reported to have duchenne muscular dystrophy or becker muscular dystrophy in the U.S. North America is expected to dominate the global muscular dystrophy treatment market, owing to the absence of marketed pharmacological therapies indicated to treat muscular dystrophy, rising prevalence of the disease, and rising research and development for producing effective drugs. Europe is expected to boost the market growth over the forecast period, owing to growing public awareness and increasing research activities.
Key players operating in the global muscular dystrophy treatment market include Santhera Pharmaceuticals, PTC Therapeutics, BioMarin Pharmaceutical, Sarepta Therapeutics and Eli Lilly. The approval and launch of oral corticosteroid Emflaza in 2017, has been found highly effective in patients to regain strength and restore their ability to walk. The other vendors include Acceleron Pharma, Capricor Therapeutics, Bristol-Myers Squibb, Lexicon Pharmaceuticals, and Pfizer.
Table of Content
Global Muscular Dystrophy Treatment Market Research Report
Section 1: Global Muscular Dystrophy Treatment Industry Overview
Section 2: Global Economic Impact on Muscular Dystrophy Treatment Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Muscular Dystrophy Treatment Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Muscular Dystrophy Treatment Market Forecast
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire